Exchange: NASDAQ·Updated 07:47 PM EDT

INSM News

News
all
press releases
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
Zacks
INSM Stock Slides on CFO Exit, Reiterates '26 Sales View
Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.
Zacks
More News
$100 Invested In Insmed 5 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 5 years by 17.45% on an annualized basis producing an average annual return of 29.54%. Currently, Insmed has a market capitalization of $22.80 billion.read more...
Benzinga
Insmed Stock Slides CFO Exit Date Set, 2026 Guidance Reaffirmed
Insmed shares slip after CFO Sara Bonstein steps down, reaffirms 2026 financial targets.read more...
Benzinga
Insmed Announces CFO Transition
Insmed Announces CFO Transition Insmed Announces CFO TransitionPR NewswireBRIDGEWATER, N.J., Oct. 5, 2026Sara Bonstein Will Step Down as CFO on October 30 After Nearly Seven Years of Dedicated LeadershipCompany Reaffirms Full-Year 2026 Financial GuidanceCompany Announces Third-Quarter 2026...
PR Newswire
Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback
LQDA faces a major setback as a patent ruling threatens Yutrepia's PH-ILD indication and creates uncertainty around its commercial outlook.
Zacks
$1000 Invested In Insmed 15 Years Ago Would Be Worth This Much Today
Insmed (NASDAQ:INSM) has outperformed the market over the past 15 years by 11.06% on an annualized basis producing an average annual return of 24.7%. Currently, Insmed has a market capitalization of $25.54 billion.read more...
Benzinga
Can LQDA's Yutrepia Outpace Intensifying PAH Competition?
Liquidia's Yutrepia posts rapid sales growth, but intensifying competition from established therapies and emerging drugs could test its momentum.
Zacks
FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce
INSM's Arikayce label expansion gets FDA priority review, potentially broadening its use in newly diagnosed MAC lung disease.
Zacks
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027
FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027 FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE (amikacin liposome inhalation suspension) for...
PR Newswire
Insmed Expands Community Impact During Fifth Annual Global Day of Good
Insmed Expands Community Impact During Fifth Annual Global Day of Good Insmed Expands Community Impact During Fifth Annual Global Day of GoodPR NewswireBRIDGEWATER, N.J., Sept. 16, 2026 Company-wide day of service brings together more than 1,350 employees to support over 50 organizations throughout...
PR Newswire

Advertisement|Remove ads.